Quizartinib + Placebo oral tablet + Cytarabine + Idarubicin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Sep 5, 2019 → Jan 24, 2025
NCT ID
NCT04107727About Quizartinib + Placebo oral tablet + Cytarabine + Idarubicin
Quizartinib + Placebo oral tablet + Cytarabine + Idarubicin is a phase 2 stage product being developed by Daiichi Sankyo for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04107727. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04107727 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia